Abstract. Background 
It is not known, however, whether blood sphingolipid levels are indicative of CRC stage. Specifically, the objective of this retrospective pilot study was to determine whether serum levels of sphingolipids are associated with stage IV CRC.
Patients and Methods
Participants and samples. Patients with stage IV CRC (n=10) and normal donors (n=10) were all Caucasian males. For normal donors, the average age was 56 (range=44-61) years. For patients with CRC, the average age was 62 (range=44-80) years; all had adenocarcinoma of the large intestine, stage IV with metastases. The details of staging and classification for the patients with CRC is provided in Table I . Each classification type was represented by one patient.
The sera of all participants were purchased from Asterand (Detroit, MI, USA). Because serum collection procedures affect normal serum sphingolipid levels in healthy individuals (7) , in order to obtain reliable measurements of serum sphingolipid levels, a standardized protocol for serum collection, freezing, and shipping is required. A global network of clinical sites that provide Asterand with biosamples is expected to comply fully with those standards, as well as conduct subject recruitment, obtain informed consent, and conduct scientific activities in accordance with applicable laws, regulations, and ordinances (cf. http://www.asterandbio.com/ company/ethics/). At a clinical site, after initial diagnosis, blood was drawn immediately prior to anesthesia/surgery. The frozen sera were shipped on dry ice from Asterand to the Lipidomics Core (Medical University of South Carolina, Charleston, SC, USA) for mass spectrometric analysis.
Mass spectrometric analysis of sphingolipids. After thawing, lipids were extracted from 100-μl aliquots of sera. Sphingolipids were separated by high-performance liquid chromatography, introduced Stage Classification IV T2N2bM1: Tumor invades muscularis propria; metastasis in 7 or more regional lymph nodes; distant metastasis. T3N0M1: Tumor invades through the muscularis propria into the pericolorectal tissues; no regional lymph node metastasis; distant metastasis. T3N1bM1: Tumor invades through the muscularis propria into the pericolorectal tissues; metastasis in 2-3 regional lymph nodes; distant metastasis. IVA T3N0M1a: Tumor invades through the muscularis propria into the pericolorectal tissues; no regional lymph node metastasis; metastasis confined to 1 organ or site (e.g. liver, lung, ovary, nonregional node). T3N1bM1a: Tumor invades through the muscularis propria into the pericolorectal tissues; metastasis in 2-3 regional lymph nodes; metastasis confined to 1 organ or site (e.g. liver, lung, ovary, nonregional node). T3N2aM1a: Tumor invades through the muscularis propria into the pericolorectal tissues; metastasis in 4-6 regional lymph nodes; metastasis confined to 1 organ or site (e.g. liver, lung, ovary, nonregional node). T3N2bM1a: Tumor invades through the muscularis propria into the pericolorectal tissues; metastasis in 7 or more regional lymph nodes; metastasis confined to 1 organ or site (e.g. liver, lung, ovary, nonregional node). T4aN0M1a: Tumor penetrates to the surface of the visceral peritoneum; no regional lymph node metastasis; metastasis confined to 1 organ or site (e.g. liver, lung, ovary, nonregional node). T4aN1aM1a: Tumor penetrates to the surface of the visceral peritoneum; metastasis in 1 regional lymph node; metastasis confined to 1 organ or site (e.g. liver, lung, ovary, nonregional node). IVB T3N0M1b: Tumor invades through the muscularis propria into the pericolorectal tissues; no regional lymph node metastasis; metastases in more than 1 organ/site or the peritoneum. to an electrospray ionization source, and then analyzed by tandem mass spectrometry using a TSQ 7000 triple quadrupole mass spectrometer (Thermo-Fisher Scientific, Waltham, MA, USA) (7). The analyses included the full panel of sphingolipids, including ceramides, C16-dihydroceramide, sphingosine, sphingomyelins and hexosylceramides.
Statistical analysis. Differential concentration analysis:
Sphingolipid concentrations were log 2 transformed and compared between CRC and control groups using two-sample t-tests assuming equal variance. The difference in mean log concentration was converted into linear fold changes. p-Values were adjusted using the false-discovery rate method (8) to obtain q-values. Differential concentration was inferred based on values of q<0.05 and fold change >1.5. In addition, a global test of association at the sphingolipid family level was conducted using the globaltest package in R statistical language environment (9) . The null hypothesis for this test was that no sphingolipid in the family is associated with the outcome, i.e. with CRC vs. CRC-free. The three sphingolipid families tested were ceramides (12 individual ceramides), sphingomyelins (11 individual sphingomyelins), and hexosylceramides (nine individual hexosylceramides). Correlation analysis: The correlation of concentrations of pairs of individual serum sphingolipids from patients and controls was assessed using Pearson correlation. Pairs of sphingolipids were considered significantly correlated provided that the adjusted pvalues were less than 0.05 and the absolute correlation coefficient (r) was greater than 0.50. A hierarchical clustering of the matrix of correlation values with a Euclidean distance was performed using the heatmap function in R. Table II shows the differential analysis of the concentrations of 38 sphingolipids in sera obtained from CRC patients and controls. Serum sphingolipid levels from controls are similar to published serum sphingolipid levels from normal donors (7) . Serum levels of six sphingolipids were significantly altered in patients with stage IV CRC compared to controls. The levels of C16-, C18-, C18:1-and C24:1-ceramide, as well as those of sphingosine, were significantly higher, and the levels of C24-sphingomyelin were significantly lower compared to controls (Table II; Figure 2) . Moreover, the global test of association for the three families of sphingolipids showed that ceramides (p=0.01) and sphingomyelins (p=0.00025) were significantly associated with CRC, but not hexosylceramides (p=0.24). The data suggest that ceramides and sphingomyelins but not hexosylceramides were implicated in stage IV CRC.
Results and Discussion
The heatmap depicted in Figure 3 summarizes the results of correlation analysis for serum sphingolipids from patients with CRC and normal donors. Three prominent clusters consisting of ceramides, sphingomyelins, and hexosylceramides were identified as significantly positively correlated (Figure 3 , details D1, D2, and D3, respectively). A cluster of ceramides that was negatively correlated with the cluster of sphingomyelins was also identified (D4 in Figure 3) .
We found 100 pairs of sphingolipids that were significantly correlated in both CRC and control groups (not shown). Among these, C18-and C18:1-ceramide were highly positively correlated (r=0.93), as well as C16-ceramide and C18-ceramide (r=0.90). DihydroC16-ceramide and C16-ceramide were also positively correlated (r=0.86). Because dihydroC16-ceramide is a metabolite from the de novo biosynthesis sphingolipid pathway, the data suggest that this pathway modulates blood levels of sphingolipids. Because the levels of C18-and C16-ceramide were higher in the CRC group compared to the control group, the data suggest enhanced up-regulation of CerS1 and CerS6, respectively, in patients with CRC.
A significant negative correlation was found for C22:1-sphingomyelin and C22:1-ceramide (r=−0.51) in both CRC and control groups. However, there was no significant correlation for C24-ceramide and C24-sphingomyelin, which had significantly lower levels in serum in patients with CRC (Table II, Figure2) . The data suggest that if the blood levels of ceramide were affected by a sphingomyelinase, this was not a distinctive feature associated with stage IV CRC. Sphingosine can be made from ceramide via ceramidase. If the blood levels of sphingosine were modulated by ceramidase, one would expect a negative correlation between sphingosine and ceramide. We observed, however, significant positive correlation for sphingosine and C18-ceramide, as well as for sphingosine and C16-ceramide (r=0.61 for both pairs) in CRC patients and normal donors. The data from the correlation analysis do not support the role for ceramidase in sphingosine generation in CRC patients and normal donors or for the elevated sphingosine levels in CRC patients compared to controls. The data imply that a host response might have been reflected in observed significant changes in serum levels of sphingosine, as well as the four individual ceramides and C24-sphingomyelin in patients with CRC (cf. 10, 11) .
One of the limitations of this study is that long-term outcomes of patients with CRC whose biosamples were used were not provided by Asterand. However, the immediate purpose of this novel preliminary study was to investigate the possibility that sphingolipids can serve as blood biomarkers indicative of stage IV CRC. Because we did observe significant alterations in the serum sphingolipid profile associated with stage IV CRC, a retrospective study using cohorts with known outcomes to validate the role of dysregulated sphingolipid metabolism as a predictor of mortality in patients with CRC is warranted.
Another limitation of the study is the small sample size. While we recorded significant results in spite of the small sample size, replication is needed in larger studies to confirm the findings. A study that includes patients with earlier stages of CRC is also warranted. In addition, mass spectrometry detected hexosylceramides and did not isolate glucosylceramides from galactosylceramides. These two lipids are isomers and require more time-consuming techniques to separate. As this was the first pilot study of these serum lipids in patients with CRC, these more extensive techniques were not conducted. We hypothesize that hexosylceramides reflect the levels of glucosylceramides, and not galactosylceramides. Future studies will need to verify this hypothesis by quantifying serum levels of each sphingolipid.
In conclusion, the present novel data suggest that sphingolipid metabolism is perturbed in the blood of patients with stage IV CRC, and that sphingolipids have the potential for serving as novel, non-invasive, inexpensive, and effective blood-based biomarkers to complement CRC staging for better prognoses and more personalized medicine.
